MyChesCo on MSN
Larimar Reports Promising Friedreich’s Ataxia Data as Nomlabofusp Nears Phase 3 Launch
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced third-quarter 2025 financial results and a clinical ...
Researchers at UT Southwestern Medical Center have identified synthetic RNA and DNA that reverses the protein deficiency causing Friedreich's ataxia, a neurological disease for which there is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback